NCT03980769View on ClinicalTrials.gov

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder
Interventions
DRUG

Thiotepa

Given IV

DRUG

Treosulfan

Given IV

DRUG

Fludarabine Phosphate

Given IV

BIOLOGICAL

Rabbit Anti-Thymocyte Globulin

Given IV

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo HCT via infusion

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

Fred Hutchinson Cancer Center

OTHER